IDEAYA Biosciences, Inc. Common Stock (IDYA)

Price$28.29

Value ScoreC

Growth ScoreA

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-28.50%

Price vs S&P 500 (4W)-0.10%

VGM Score59.73

Market Capitalization$2.49B

All Metrics

Book Value / Share (Quarterly)$10.67

P/TBV (Annual)5.83x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)62.54%

Cash Flow / Share (Quarterly)$-1.00

Price vs S&P 500 (YTD)-26.32%

Net Profit Margin (TTM)-27.77%

EPS (TTM)$-1.60

10-Day Avg Trading Volume0.76M

EPS Excl Extra (TTM)$-1.60

Revenue Growth (5Y)62.10%

EPS (Annual)$-1.28

ROI (Annual)-11.11%

Net Profit Margin (5Y Avg)-949.88%

Cash / Share (Quarterly)$7.64

Revenue Growth QoQ (YoY)55.37%

ROA (Last FY)-10.25%

Revenue Growth TTM (YoY)3118.14%

EBITD / Share (TTM)$-2.04

ROE (5Y Avg)-17.70%

Operating Margin (TTM)-42.02%

Cash Flow / Share (Annual)$-0.84

P/B Ratio2.65x

P/B Ratio (Quarterly)3.12x

Net Income / Employee (Annual)$-784,100

EV / Revenue (TTM)10.33x

ROA (TTM)-12.79%

EPS Incl Extra (Annual)$-1.28

Current Ratio (Annual)11.34x

Quick Ratio (Quarterly)10.45x

3-Month Avg Trading Volume1.07M

52-Week Price Return34.08%

Revenue / Employee (TTM)$1,553,600

Tangible BV / Share (Quarterly)$8.67

P/S Ratio (Annual)11.36x

Asset Turnover (Annual)0.20x

52-Week High$39.28

Operating Margin (5Y Avg)-1124.28%

EPS Excl Extra (Annual)$-1.28

CapEx CAGR (5Y)37.04%

Tangible BV CAGR (5Y)102.18%

26-Week Price Return-20.58%

Quick Ratio (Annual)10.97x

13-Week Price Return-14.35%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.74x

Enterprise Value$2.33B

Revenue / Share Growth (5Y)25.61%

Asset Turnover (TTM)0.20x

Book Value / Share Growth (5Y)11.63%

Revenue / Employee (Annual)$1,508,300

Pretax Margin (Annual)-51.99%

Cash / Share (Annual)$7.28

3-Month Return Std Dev44.74%

Net Income / Employee (TTM)$-962,500

ROE (Last FY)-11.11%

EPS Basic Excl Extra (Annual)$-1.28

Receivables Turnover (TTM)73.20x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.60

Receivables Turnover (Annual)73.20x

ROI (TTM)-13.92%

P/S Ratio (TTM)11.03x

Pretax Margin (5Y Avg)-949.88%

Revenue / Share (Annual)$2.47

Tangible BV / Share (Annual)$7.25

Price vs S&P 500 (52W)9.71%

Year-to-Date Return-18.17%

5-Day Price Return-2.25%

EPS Normalized (Annual)$-1.28

ROA (5Y Avg)-16.05%

Net Profit Margin (Annual)-51.99%

Month-to-Date Return-4.00%

Cash Flow / Share (TTM)$-1.89

EBITD / Share (Annual)$-1.77

Operating Margin (Annual)-72.84%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-17.70%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.60

P/TBV (Quarterly)4.01x

P/B Ratio (Annual)2.96x

Pretax Margin (TTM)-27.77%

Book Value / Share (Annual)$11.65

Price vs S&P 500 (13W)-22.61%

Beta-0.05x

P/FCF (Annual)45.22x

Revenue / Share (TTM)$2.54

ROE (TTM)-13.92%

52-Week Low$20.45

vGradeC

gGradeA

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-1.11est. -1.01

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.24

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
IDYAIDEAYA Biosciences, Inc. Common Stock	C	A	C	$28.29
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

IDEAYA Biosciences is an oncology-focused precision medicine company developing targeted cancer therapies selected using molecular diagnostics and biomarker validation. It combines small molecule drug discovery with translational research to identify patient populations most likely to benefit from its treatments. The company has six clinical-stage candidates and multiple earlier-stage preclinical programs in development.